We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Monoclonal Antibody Treatment Blocks Lymphoma Progression in Mouse Model

By LabMedica International staff writers
Posted on 16 Aug 2016
Print article
Image: Blocking JAM-C on lymphoma cells inhibits their migration through vessel walls (Photo courtesy of the Université de Genève).
Image: Blocking JAM-C on lymphoma cells inhibits their migration through vessel walls (Photo courtesy of the Université de Genève).
Immunotherapy based on monoclonal antibodies that specifically bind to the surface protein junctional adhesion molecule (JAM)-C, which is expressed by a variety of different cell types, including human B lymphocytes and some B-cell lymphoma subtypes, blocked progression of lymphoma in a mouse xenograft model of mantle cell lymphoma.

Previous studies had shown that treatment with anti-JAM-C polyclonal antibodies reduced homing of human B cells to lymphoid organs in a NOD/SCID mouse model. In the present study, which was published in the June 2, 2016, online edition of the Journal of Leukocyte Biology, the role of JAM-C in the engraftment of human lymphoma B cells in mice was investigated.

Investigators at Université de Genève (Switzerland) worked with the "H225" monoclonal antibody that had been designed to bind solely to JAM-C. They found that administration H225 reduced tumor growth of JAM-C+ MCL cells in bone marrow, spleen, liver, and lymph nodes of mice. Treatment with anti-JAM-C antibodies significantly reduced the proliferation of JAM-C-expressing lymphoma B cells. Moreover, the binding of anti-JAM-C antibodies inhibited the phosphorylation of ERK1/2, without affecting other signaling pathways.

"Since they cannot survive in the blood for long, these malignant cells are compelled to find a more accommodating environment - such as the lymphatic system - where they can proliferate. We decided to focus on this Achilles heel by containing them in the blood so as to prevent any resulting harm," said senior author Dr. Thomas Matthes, professor of medicine at Université de Genève.

In other words, masking JAM-C expression with H225 prevented more than 50% of lymphoma cells from migrating out of blood vessels and into the lymphoid organs where they could have developed into lymphoma tumors. "This is not its only effect," said Dr. Matthes, "H225 also significantly limited cell proliferation, even when tumor cells had already settled in the lymphatic system. In our mice, we observed the nearly-complete disappearance of already-present tumor cells in the organs."

Related Links:
Université de Genève

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: The QIAstat-Dx Respiratory Panel Plus has received U.S. FDA clearance (Photo courtesy of QIAGEN)

New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results

Respiratory tract infections are a major reason for emergency department visits and hospitalizations. According to the CDC, the U.S. sees up to 41 million influenza cases annually, resulting in several... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more